Obesity Market Could Add Two New Therapies In The Near Term, Pfizer Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The obesity drug market could potentially see two new entrants in the near term, Pfizer VP-U.S. Cardiovascular Medical Group Gary Palmer, MD, said Dec. 1 at the Health Care Research & Innovations Congress in Washington, D.C
You may also be interested in...
Pfizer Focusing Obesity Rx Development Efforts On Combination Therapies
The company's antihypertensive/cholesterol-lowering agent Caduet and the atorvastatin/torcetrapib combination have potential for use in metabolic syndrome, Pfizer VP-Cardiovascular Medical Group Palmer says. Future obesity therapies will require comparable efficacy to Abbott's Meridia but with a more tolerable safety profile, he says.
Pfizer Focusing Obesity Rx Development Efforts On Combination Therapies
The company's antihypertensive/cholesterol-lowering agent Caduet and the atorvastatin/torcetrapib combination have potential for use in metabolic syndrome, Pfizer VP-Cardiovascular Medical Group Palmer says. Future obesity therapies will require comparable efficacy to Abbott's Meridia but with a more tolerable safety profile, he says.
J&J Weighs Topamax Controlled-Release Formulation After Dropping Obesity Program
Controlled-release topiramate was designed to avoid dosing and tolerability issues seen in obesity trials with immediate-release formulation. Phase II study in diabetes-related obesity shows no advantage for long-acting version, J&J says; the formulation remains under evaluation for other indications.